Objectives: Treatment of oligometastatic patients is a current challenge in radiation oncology. Aim of this study is to define a dose-response relationship for hypofractionated radiotherapy of oligometastases.
Methods: Retrospective analysis of metastases treated by hypofractionated stereotactic radiotherapy was performed. Delivered dose was calculated both as biological effective dose (BED), and as ratio between BED and the logarithm of metastasis volume (BED logVolume Ratio, BVR). Two dose-response models were defined by logistic regression. The fitted outcome was the Metastases Complete Response (MCR). Performances of the models were assessed by area under the receiver operating curve (AUC) and by bootstrap calibration of original data. BED and BVR impact on survival outcomes has been evaluated.
Results: Fifty-three patients with 79 metastases were analyzed. AUC and calibration of BVR-based logistic model showed better accuracy in predicting MCR with respect to BED-based model. No significant difference between the two ROCs was observed (De Long test p value > 0.05), but significant discordance in calibration resulted in the BED model (p value < 0.05 in Hosmer-Lemeshow Goodness of fit test). BVR returned also better results in multivariate analyses for survival outcomes.
Conclusions: The ratio between BED and the logarithm of metastasis volume (BVR), as a corrective factor for fitting the probability of metastases response to stereotactic radiotherapy, could be a tool for evaluating and prescribing treatments for oligometastatic disease. BVR can be useful for producing more reliable survival statistics too.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-018-1206-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PROshot: Hypofractionated Postmastectomy Radiation, Palliative Liver Radiation, Celiac Plexus Radiosurgery, Perioperative Chemoradiation for Gastric Cancer, and Prostate Stereotactic Body Radiation Therapy Versus Prostatectomy.
Pract Radiat Oncol
January 2025
Department of Radiation Oncology, Ascension St. Vincent's East, Birmingham, Alabama.
Reirradiation of gliomas with hypofractionated stereotactic radiotherapy: efficacy and tolerance analysis at a single center.
Rep Pract Oncol Radiother
December 2024
Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
Article Synopsis
- Recurrent high-grade gliomas pose a treatment challenge; this study evaluates the effectiveness and tolerability of Hypofractionated Stereotactic Radiation (HFSRT) in re-irradiation.
- A retrospective analysis of 52 patients treated between 2011 and 2021 showed median overall survival of 12 months, with re-irradiation doses differing among patients.
- The treatment was mostly well-tolerated, with minimal severe side effects, indicating HFSRT as a promising option for managing these tumors.
Challenges in assessing national radiotherapy costs: application of the ESTRO-HERO model in Spain.
Front Public Health
January 2025
Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet Barcelona, Barcelona, Spain.
Background And Purpose: The aim was to estimate the cost of the external beam radiotherapy (EBRT) in public health care centers in Catalonia (Spain), according to the ESTRO-HERO costing model for 2018.
Materials And Methods: Personnel, equipment, and activity data from 2018 from the 11 RT centers were used, incorporating European mean values adapted to the Catalan context. Secondly, EBRT costs were estimated, incorporating 2023 fractionation technique and scheme usage percentages.
Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer.
Radiat Oncol J
December 2024
Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
In this paper, we review the use of hypofractionated radiotherapy for gastrointestinal malignancies, focusing on primary and metastatic liver cancer, and recurrent rectal cancer. Technological advancements in radiotherapy have facilitated the direct delivery of high-dose radiation to tumors, while limiting normal tissue exposure, supporting the use of hypofractionation. Hypofractionated radiotherapy is particularly effective for primary and metastatic liver cancer where high-dose irradiation is crucial to achieve effective local control.
View Article and Find Full Text PDFPreoperative versus postoperative stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis of comparative studies.
Neurosurg Rev
January 2025
Department of Neurological Surgery, University of Virginia, Charlottesville, USA.
Resection is often the primary treatment for large brain tumors but is less practical for multiple brain metastases (BM). Current guidelines recommend stereotactic radiosurgery (SRS) for untreated BMs or following the surgical removal of a solitary BM to reduce the risk of local tumor recurrence. Preoperative SRS (pre-SRS) shows promise with fewer complications and more precise targeting, but it lacks tissue diagnosis and may hinder wound healing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!